Physiologically based pharmacokinetic (PBPK) modeling was used to -m the low-dose exposure of patients to the carcinogen 2,4-toluenediamine (2,4-TDA) rdeased from the adation ofthe polyester urethane foam (PU) used in Meme silicone breast implants. The tissues are represnted as five compartments: liver, Idney, gasrointestinal tract, slowly perfused tissues (e.g., fat), and richly perfused tissues (e.g., muscle). The PBPK model w tted to the plasma and urine concentrations of 2,4-TDA and its metabolite 4-AAT (4-N-aetyl-2-amino toluene) in rats given low doses of 2,4-TDA intravenously and subcutaeously. The rat modaldwas extrapolated to simulate oral and implant routes in rats. After adjusting for human physiological parmeters, the model was then used to predict the bioavailability of 2,4-TDA released from a typical 4. Polyurethanes have been used in breast implant covers, pacemaker leads, hemodialyzer potting material, and other medical applications. The degradation of polyurethanes in vivo has long been a concern due to both the release of potentially harmful materials as well as mechanical failure. The composition of the polyurethane degradation products depends on the original formulation of the polymer. The polyester urethane (PU) foam cover of the Meme breast implant (or Replicon; Surgitek Corporation, Racine, WI) was made from a polyester resin and a 80:20 mixture of 2,4-toluene diisocynate and 2,6-toluene diisocyanate (2,4-TDI, 2,6-TDI) (1). One of the degradation products of TDI is 2,4-toluenediamine (2,4-TDA). Data in experimental animals showed that the PU foam cover degraded within 6-12 months of implantation (2). This result was consistent with the clinical observations in patients with Meme breast implants (3,4). Our own in vitro studies indicated that 2,4-TDA was slowly released over time by hydrolytic degradation when PU foam samples were incubated under mild physiological conditions (5,6). The amount and rate of 2,4-TDA production observed in vitro varied with the conditions of PU foam exposure (7-9). The carcinogenicity of 2,4-TDA was studied extensively in mice, rats, and other species (10)(11) (12) (13) (14) (15) (16) (17) (18) (19) (25) . The kinetic behavior of 2,4-TDA and its metabolite were derived from the implant PBPK model for both rats and humans. The simulated results were compared to the available independent data for validation (10-13,22,2,) with an experimentally determined value of 88 ng 2,4-TDA/g foam/day as previously reported (5,6). The degradation of the PU foam in vivo was assumed to produce only one product, 2,4-TDA (29). The PBPK model for 2,4-TDA accounts for hepatic metabolism, which is known to produce an active metabolite (18, 19) . Although there were at least eight known metabolites of 2,4-TDA in the liver, 2,4-TDA was assumed only to have one metabolite, 4-acetylamino-2-aminotoluene (4-AAT), in this model for simplicity (19, 29) . The rate of production of 4-AAT was controlled by an adjustable selectivity in the model (19) . The selectivity was defined as the fraction of metabolites of 2,4-TDA that were converted to 4-AAT. The value of the selectivity was set according
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Physiologically based pharmacokinetic (PBPK) modeling uses physiological parameters such as organ volumes, blood flows, and excretion flows, and chemical specific parameters such as tissue solubility and biotransformation rates. This type of modeling uses these physiological parameters to complete a material balance on the component of interest in the body. An important feature of this type of model is predicting the absorption, distribution, metabolism, and elimination of the simulated chemical. Animal data using one uptake route can be extrapolated to another route and/or from animal species to humans with minor changes to the PBPK model. The extrapolative value of this approach in human health risk assessment has long been used for many drugs and chemicals (25) (26) (27) (28) .
The objectives of this study were to develop a PBPK model to simulate the fate of low-dose exposure of 2,4-TDA from implant degradation and assess the potential health risk in patients with Meme PU foam-covered silicone breast implants. The PBPK model was initially developed to fit experimental data obtained in rats injected intravenously (iv) and subcutaneously (sc) with low doses of 2,4-TDA, 0.54 mg/kg and 0.44 mg/kg, respectively (29) . Once the PBPK model adequately simulated the fate of 2,4-TDA and its metabolite by different routes of exposure, the model was scaled up to a human PBPK model using appropriate physiological and pharmacokinetic parameters. The model was solved numerically using an adaptive grid RungeKutta method in the Mathcad PLUS 6.0 software package (MathSoft, Cambridge MA). Using sensitivity analysis, we evaluated the rat model and determined the ratelimiting steps that changed with doses, routes, and species. Statistical validation of the fit of the experimental rat results to the PBPK model simulation results was performed as described by Krishman and Anderson (25) . The kinetic behavior of 2,4-TDA and its metabolite were derived from the implant PBPK model for both rats and humans. The simulated results were compared to the available independent data for validation (10-13,22,2,). Finally, a quantitative risk assessment was performed to assess the potential cancer risks in patients with Meme silicone breast implants.
Methods PBPK model The model consists of five tissue compartments: two excreting compartments [kidney and gastrointestinal (GI) tract], slowly perfused tissues (e.g., fat), richly perfused tissues (e.g., muscle), and metabolizing tissue (liver). The model is very similar to styrene and methylene chloride PBPK models (27, 28) . The hydrolytic PU foam degradation rate constant, Kd, was zero order with an experimentally determined value of 88 ng 2,4-TDA/g foam/day as previously reported (5, 6) . The degradation of the PU foam in vivo was assumed to produce only one product, 2,4-TDA (29) . The PBPK model for 2,4-TDA accounts for hepatic metabolism, which is known to produce an active metabolite (18, 19) . Although there were at least eight known metabolites of 2,4-TDA in the liver, 2,4-TDA was assumed only to have one metabolite, 4-acetylamino-2-aminotoluene (4-AAT), in this model for simplicity (19, 29) . The rate of production of 4-AAT was controlled by an adjustable selectivity in the model (19) . The selectivity was defined as the fraction of metabolites of 2,4-TDA that were converted to 4-AAT. The value of the selectivity was set according to the published fraction of metabolites that were 4-AAT (0.32) (1,9. The metabolite 4-AAT was also distributed, metabolized to an unknown product, and excreted (11). 2,4-TDA was modeled to be an equilibrium system between protein-bound and free 2,4-TDA, with the ratio of bound to free kept constant so that 9.7% of the 2,4-TDA was free, as shown in the initial experimental rat plasma samples (29) . As shown in Figure 1 , blood of uniform composition exiting the mix point flowed through the implant into the arterial circuit. The uniformly mixed arterial blood was then distributed to other compartments in the body. The blood flow rate to each compartment was determined from published physiological measurements (26) . The distribution coefficient (D), which related to the blood/tissue partition coefficient (Jf, was defined as the ratio of the concentration of 2,4-TDA or metabolite in the tissue to its emergent venous blood concentration. The 2,4-TDA (and 4-AAT) distribution coefficients and metabolism rate constants were obtained from previously published radioactive distribution studies in rats and mice (11) (12) (13) . Venous Experimental data. Three sets of independent experimental data were used to calibrate the model (29) . After iv injection with 0.52 mg/kg 2,4-TDA, blood samples were collected from five female CDF (F-344)/Crl rats at various time intervals (0.05, 0.15, 0.25 hr, etc.) up to 48 hr after dosing. Both the 2,4-TDA and 4-AAT plasma results were measured by a validated GC/MS analytical method with a detection limit of 0.1 ng/ml. These results were used to fit the metabolism parameters for both 2,4-TDA and 4-AAT in the model. As discussed previously, distribution coefficients were assigned from radioactive distribution studies (11,12,16).
Urine was obtained for analysis after female CDF (F-344) CRL BR rats (n = 5) received a single sc injection of 2,4-TDA (0.44 mg/kg). The mean fraction of 2,4-TDA excreted unchanged was 0.22% (range 27-51 ng/ml). The corresponding concentration of urinary 4-AAT recovered was less than 1% (range 103-188 ng/ml) within 48 hr after dosing. These results were used to set the urine/feces excretion distribution coefficients.
In another study, a 14C-labeled foam was 
Results
Calibration using iv bolus andsc administration ofa low dose of2,4-TDA in the rat. The fitted experimental plasma concentrations following iv injection of a 0.52-mg/kg dose 2,4-TDA are shown in Figure 2 . 2,4-TDA plasma levels decreased rapidly following iv administration in rats. Although this dose would be expected to produce a blood concentration of6,500 ng/mi in the rat, the maximum initial plasma concentration was 633 ng/ml, indicating that 2,4-TDA was rapidly bound to plasma proteins confirming previous observations (22. The blood flow parameters; and compartment volumes were set from published physiological parameters; the tissue distribution coefficients were obtained from published radioactive distribution studies as discussed earlier (11) (12) (13) 26) . Even with these constraints, the model was robust enough to accurately correlate the experimental results using only the metabolism parameters for both 2,4-TDA and 4-AAT. From the material balance results, the area under the serum concentration time curve (AUC) of 2,4-TDA from time zero to infinity was determined to be 62.176 ng/hr/ml, the total body dearance (Cl) was 8,363 ml/hr, and the volume of distribution (7Vd) was 1,379 ml/kg (30) . The elimination half life (tl2) of free 2,4-TDA in the plasma was 0.074 hr due to its extensive binding to plasma proteins (22) . The protein bound 2,4-TDA is in equilibrium with the free 2,4-TDA, which is biologically active. The extent that protein binding influences the delivery of free 2,4-TDA to the target organ may change in certain human disease states (30) . After the first 6 hr, the plasma levels of 2,4-TDA dropped to a very low value below the analytical detection limits. As shown, most of the administered dose of 2,4-TDA was rapidly metabolized, and very little was excreted or absorbed (0.22%). The urinary concentration of 4-AAT reached nearly 500 ng/ml, well above detection limits, even though less than 0.3% (weight) of the original dose was excreted. Thus, the predicted cumulative concentrations of 4-AAT excreted in the urine were well fitted to the urine analysis data obtained from the rat subcutaneous study (29 Time (hr) the distribution coefficients and relative excretions were the same in these calculations. In the human, this corresponds to a plasma level of 16 x 104 ng/ml of total 2,4-TDA (free + conjugated; 9.7% free). Similar to the rat implant we do not recommend using free plasma 2,4-TDA to monitor the breakdown of PU foam from breast implants. However, urinary 4-AAT may be a better biomarker (0.309% or 0.96 nglml). (16) . Along with the results for the iv bolus and the implant, the plasma 2,4-TDA and 4-AAT concentrations are shown in Figures 3 and 4 , respectively. At a given low dose, the model predicted lower plasma concentrations of free 2,4-TDA and 4-AAT following the oral route compared to iv bolus due to slower absorption rate. However, these concentrations persisted for a much longer period of time, so the area under the plasma concentration time curve was equivalent (AUC = 58.95 ng/hr/ml) compared to exposure from the iv route. The 4-AAT urinary concentration reached a maximum of 240 ng/ml after about 1 hr, a very comparable level to the sc result because the 2,4-TDA was introduced gradually in both cases. The cumulative urinary level of 4 (25) of just how well the experimental rat results fitted the PBPK simulation results, the log (base 10) transformed 2,4-TDA rat blood data were shown to follow the same linear model as the log (base 10) transformed 2,4-TDA PBPK model predictions, over the first half hour, i.e., no statistically significant difference for either slope or intercept between the transformed data and the transformed predictions, even at the 10% significance level. For the 4-AAT, the residuals or differences between the log (base 10) transformed 4-AAT rat blood data and the log (base 10) transformed 4-AAT PBPK model predictions from 0.05 to 0.5 hr were shown to have a zero mean, no statistically significant difference from zero even at the 40% significance level, and a 90% tolerance interval with 90% coverage for individual residuals of 43% and 202% for the rat data as percent of model prediction.
Discussion
In the safety evaluation of the PU foam-covered breast implants, it is difficult to assess the carcinogenic potential of the Meme breast implants relative to 2,4-TDA, a mutagen and carcinogen known to be released from the device (20) (21) (22) (23) (24) . The data available for this purpose are generally high-dose feeding (4.7-10.6 mg/kg) animal data (14) (15) (16) 18, 151) . Therefore, we need pharmacokinetic models that rely on realistic physiological parameters and chemical-specific parameters to be able to extrapolate between high and low doses, different routes of administration, and from animal to human (25) . The objective of this paper is to use the PBPK model for 2,4-TDA in rats to predict the long-term distribution, excretion, and metabolism of the low-dose infusion cases that are characteristic in humans with breast implant degradation. The PBPK model for 2,4-TDA adequately simulated the experimental 2,4-TDA and 4-AAT rat plasma data (Fig. 2) . The fit of the experimental rat results to the PBPK model simulation results was validated statistically as shown earlier (25) . Table 2 shows the pharmacokinetic data of 2,4-TDA between three simulated routes of exposure in rats. The data obtained from the mass balance studies shed light on how the implant route produces a large volume of distribution (1Vd = Dose/ Cmax = 54,900 ml/kg). Such a large Vd reflects high tissue uptake and accumulation of the initial dose of free 2,4-TDA and metabolites in target tissues such as the liver, kidney, and fat ( Table 2 ). As shown, the simulated data obtained in this study agree well with the distribution studies using radiolabeled 2,4-TDA in animals, which indicated the highest accumulation of 2,4-TDA and metabolite in the richly perfused tissue, slowly perfused tissue, GI tract, kidney, and liver (11-13,16).
The model also predicts a slow excretion of2,4-TDA from an implant (5% excreted in urine in the first week and 0.94% excretion in the feces) compared to an iv bolus and oral administration at a given dose, confirming the experimental results obtained following implantation with "4C 2,4-TDAlabeled-foam (80 mg/kg) in which approximately 2% of the total radioactivity was excreted after 56 days (29) . As shown in Table 2 , the PBPK model predicts that the continuous low-dose infusion of 2,4-TDA produced by PU foam hydrolysis from breast implants produces a very small AUC (2 x 104 ng/hr/ml). The very small AUC is due to both a slow rate of degradation of the implant, which is assumed in this model to be similar to the rate obtained in vitro (88 ng 2,4-TDA/g of foam per day under mild simulated physiological conditions) (5, 6 ). In addition, most 2,4-TDA produced from the breakdown of the PU foam cover is extensively bound to plasma protein (9.7% free).
The plasma protein binding of 2,4-TDA was obtained experimentally in the rat iv study (90.3% bound).
The model-predicted results in this study confirmed that carcinogenic degradation products that are produced from implanted PU foam are stored in target organs and small amounts are excreted in animals and humans (2, (20) (21) (22) (23) (24) 251 ). Although there is no data available at this time to show a cause and effect relationship between the use of this PU foam and production of cancer in humans, the lifetime duration of exposure of the device, the high tissue uptake, and slow dearance of 2,4-TDA from breast implants are important factors contributing to the potential hazard of 2,4-TDA released from the PU foam-covered breast implants in humans (30) . Indeed, in distribution studies, the levels in every organ tested at 24 hr was reported to be higher in the rat than in the mouse, indicating more toxicity with slower dearance and larger distribution in rats; this is consistent with the higher cancer rate in rats than in mice (11-13).
At a given low dose, the iv bolus and the oral administration have about the same clearance and equivalent AUC as shown in (16) . Therefore, the model-predicted data confirm earlier findings that suggest the susceptibility to carcinogenic effects of 2,4-TDA is also dependent on the route of administration that affects 2,4-TDA kinetic behavior and thus the dose to target organs (16) .
As shown in Figure 4 , the predicted steady state plasma concentration W,,) of free 2,4-TDA in the rat is very low (only 3.4 x 10-5 ng/ml), too low to be detected by the current state of the art analytical instrumentation (detection limits <0.1 ng/ml). However, the pharmacokinetic data derived from this PBPK model can be used to determine the total daily dose and to estimate exposure. The standard pharmacokinetic equation that relates infusion rate, steady state plasma concentration, and dearance of a chemical is as follows:
Infusion rate R = C. x Clearance.
This equation predicts the rate of release of free 2,4-TDA from the implants in vivo by assuming that the release rate is equivalent to a constant slow infusion. Therefore, in the rat model, Release Rate = C x Clearance = 3.4 x 10-5 ng/ml x 9,320 ml/hr/kg = 0.317 ng/hr/kg = 0.317 x 24 hr/day/1,000,000 ng/mg = 7.60 x 10-mg/kg/day.
As such, the PBPK model provides a quantitative estimate of exposure that relates both plasma steady state level and dearance rate. Estimated human health risks from breast implants. Essentially, to estimate human risks, we have to derive the human exposure from the release rate of 2,4-TDA from the breast implants using the results of the human PBPK simulation shown in Table 2 . As with the rat, the dearance is calculated using the model by dividing the AUC by the total administered dose (30).
The model predicts that the C. of plasma free 2,4-TDA is 1.55 x 10-4 ng/ml (9.7% free) in a patient with 4.87 g PU foam in the Meme breast implants and a body weight of 58 kg. This corresponds to a plasma level of 16 x 10-4 ng/ml of total 2,4-TDA (free + conjugated). Thus, the release rate of 2,4 TDA from the foam is as follows:
Release Rate = 16 x 10-4 ng/ml x 2,175 ml/hr/kg = 3.48 ng/kg/hr = 3.48 x 24 hr/day/1,000,000 ng/mg = 83.52 x 10-mg/kg/day. This corresponds to a lifetime average daily dose (LADD) of 11.93 x 10-mg/kg/day, assuming that the lifetime of the implant was 10 years (10/70). Therefore (2) (3) (4) . Although the susceptibilities of the PU foam to water, buffer, oxygen, and enzymes at physiological conditions are known (2-9), the actual leach rate of 2,4-TDA in vivo is not well documented. Another factor that would affect the bioavailabiity of 2,4-TDA is plasma protein binding, which was lower in the clinical study reported by Sepai et al. (22) . Thus, PBPK models are limited by available biochemical data such as leaching rate and protein binding, etc; however, they are effective tools for evaluating the safety of 2,4-TDA released from implants.
In general, the risk assessment process has often relied on a number of assumptions that make it imprecise in determining the level of exposure of toxic chemicals (at acceptable risks) to the human population. In this aspect, the PBPK model, which used both physiological parameters (such as organ volumes, blood flows, etc.) and chemical-specific parameters (such as tissue distribution coefficients and biotransformation rates), can be used to predict the kinetics of chemicals and exrapolate between different routes of conmpound administration and species. ,'.,.,..,....,.,.,."",.....,.....,..,,.. . ' . " . . . . , , . , . . . . . . . , . , . . , . , . . , . . . , . , ! , . . . , . . . , . . , ...,..,.,.,-."-.."', . , , , . , , . . . -, . , , . . , . , . , . . . , . . , . -------' ,,, , , -`"---'--, . . . , . . , . . ...
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